We strongly advise you to harness Immune Pharmaceuticals fundamental analysis to find out if markets are presently mispricing the organization. In other words you can makes use of it to find out if Immune Pharmaceuticals is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We found thirty available reported financial drivers for Immune Pharmaceuticals which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Immune Pharmaceuticals fundamentals including its EBITDA and the relationship between Current Ratio and Working Capital . As Immune Pharmaceuticals appears to be a penny stock we also urge to confirm its Price to Book numbers.
Immune Pharmaceuticals Company Summary
Immune Pharmaceuticals competes with Vertex Pharmaceuticals, Dr Reddys, Zoetis, Perrigo Company, and Regeneron Pharmaceuticals. Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. Immune Pharmaceuticals operates under Drug Manufacturers - Major classification in USA and is traded on BATS Exchange. It employs 7 people.
Immune Pharmaceuticals Earnings Per Share vs Current Liabilities
Immune Pharmaceuticals is currently regarded as number one stock in earnings per share category among related companies. It is currently regarded as number one stock in current liabilities category among related companies .
|Earnings Per Share ( times )|
Immune Pharmaceuticals Market Fundamentals